ADRA2A and neoplasm: In line with the enhancement in carboplatin sensitivity observed using xylazine, dexmedetomidine, and clonidine, these findings suggest that ADRA2A activation and the consequent inhibition of cyclic AMP (cAMP) production may downregulate processes necessary for tumor cells to escape carboplatin-induced cytotoxicity.